12:19 PM
 | 
Jan 12, 2018
 |  BC Extra  |  Company News

FDA approves AZ's PARP inhibitor for breast cancer

FDA approved an sNDA from AstraZeneca plc (LSE:AZN; NYSE:AZN) and partner Merck & Co. Inc. (NYSE:MRK) for ovarian cancer drug Lynparza olaparib to treat patients with germline BRCA-mutated, HER2-negative metastatic breast cancer who have previously been treated with chemotherapy in the neoadjuvant, adjuvant or metastatic settings. The agency said the approval is the first for a PARP inhibitor outside of ovarian cancer, and the first for any drug to treat metastatic...

Read the full 334 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Extra

Article Purchase

$35 USD
More Info >